As an independent, publicly-traded biopharmaceutical company, we focus on the generation and development of fully human therapeutic antibodies using its state-of-the-art proprietary technologies. This together with more than 20 years of focused antibody discovery and optimization know-how, we boast the largest antibody pipeline with over 100 partnered and proprietary programs, 29 of which are in clinical development.
We aim to progress our portfolio of therapeutic antibodies through late stage development in partnerships and intends to build an own commercial footprint in Europe. In addition, we are interested in entering strategic alliances involving our antibody technology Ylanthia and/or our proprietary discovery stage programs. The Ylanthia technology, the industry’s largest antibody library to date with over 100 billion distinctly diverse, fully human antibodies, is optimized for rapid development and addresses the need for the delivery of antibodies against difficult targets.
MOR208 (XmAb5574) is a humanized, Fc engineered, monoclonal anti-CD19 antibody in-licensed from Xencor. Based on encouraging phase 1 and phase 2a data in CLL and NHL, MorphoSys is initiating multiple combination trials throughout 2016 with the goal to transition into the first pivotal phase 3 trial next year.
MOR202 is a fully human HuCAL-derived antibody directed against CD38, a validated and best-in-class target for the treatment of multiple myeloma. Encouraging interim data, both with regard to safety and clinical activity, from an ongoing phase 1/2a trial as a monotherapy and in combination with immunomodulatory drugs in relapsed or refractory multiple myeloma were published last year and updated data, including a deepening of the responses, will be presented during 2016.
MOR209/ES414, is an anti-PSMA/anti-CD3 bi-specific antibody based on the ADAPTIRTM platform from Emergent BioSolutions. MorphoSys entered into a joint development and commercialization agreement with Emergent in 2014, which was further amended in 2015. The partners initiated a Phase 1 clinical trial evaluating the safety, tolerability and clinical activity of the compound in patients with metastatic castration-resistant prostate cancer (mCRPC).
Phone: +49 89 89927453
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.
Click here if you notice an image that violates copyright or privacy rights.